A 8-mer Peptide of PGLYRP1/Tag7 Innate Immunity Protein Binds to TNFR1 Receptor and Inhibits TNFα-Induced Cytotoxic Effect and Inflammation
In the laboratory of molecular immunogenetics of cancer IGB RAS was demonstrated that the PGLYRP1/Tag7 innate immunity protein can be regarded as an inhibitor of TNFα cytotoxic activity via the interaction with its TNF receptor 1 (TNFR1). A C-terminal peptide fragment 17.1 of the molecule is responsible for this function. In this study was demonstrated that the minimal 8-mer region of this peptide (hereinafter – 17.1A) is capable to bind to TNFR1. As a result of such interaction, the cytotoxic signals induced by this receptor are blocked. In the Nursery for laboratory animals BIBCh RAS was demonstrates that this peptide an anti-inflammatory activity in vivo in the complete Freund’s adjuvant (CFA)-induced arthritis model in laboratory mice. Peptide 17.1A is capable to reduce periarticular inflammation, inhibit the development of synovitis and exhibit a protective effect on cartilage and bone tissues. The work was published in Frontiers in Immunology.
july 2, 2021